iBio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $100K-75.0% YoYTTM through 31 Mar 2026
Net Income -$33MTTM through 31 Mar 2026
Free Cash Flow -$23.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -35,141.0% |
| Net Margin | -33,044.0% |
Returns
-35.6%ROE
-32.2%ROA
Balance Sheet Health
Debt / Equity0.03x
Current Ratio11.88x
Net Debt-$72.5Mnet cash position
Cash & Equivalents$56.4M
Quality Metrics
Altman Z-Score-2.40
Piotroski F-Score1 / 9
FCF Margin-23,796.0%
Rule of 40-23,753.1
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2026: $100K
Diluted EPS-$0.32TTMFY2026: $-0.32
Dividend
No dividend
Capital Allocation
Capex Intensity578.0%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.